Teva Pharmaceutical Industries acquired IVAX Corporation for approximately $7.4 billion in a cash-and-stock transaction ($26 cash or 0.8471 Teva ADRs per share, subject to 50/50 proration), consolidating Teva's position as the world's largest generics company with combined revenues over $7 billion and strengthening its US and Latin American presence.
Key facts
AnnouncedJul 25, 2005
ClosedJan 26, 2006
Deal value$7.4B
Deal typeAcquisition/Merger
Therapeutic areaNeurology
Key assetsIVAX US generics portfolio, Latin American branded generics (including Mexico, Brazil), IVAX manufacturing network, Generic portfolio